Table 3.
effects of contreceptive use on metabolics parameters
| Metabolics parameters | Metabolic Score | |||||
|---|---|---|---|---|---|---|
| ΔMET1 | p-value | ΔMET2 | p-value | ΔMET3 | p-value | |
| Glycemia | −16±8.8 | 0.000 | −13±16.2 | 0.077 | 6.1±15.8 | 0.342 |
| AST | 6.1±15.8 | 0.000 | 8.3±3.5 | 0.000 | 1±1.41 | 0.110 |
| ALT | 7.6±6.5 | 0.000 | 9±1.7 | 0.000 | 0.8±2.3 | 0.355 |
| LDH | 13.5 ±74.9 | 0.397 | 5.6 ±63.3 | 0.823 | 1±53.9 | 0.962 |
| Total cholesterol | 17.9±17 | 0.000 | 20.4±6.1 | 0.000 | 5.8±7.9 | 0.097 |
| Triglycerides | 26.5 ±27.5 | 0.000 | 45.1±15.8 | 0.000 | 14±13.7 | 0.035 |
| Activity of prothrombin | −8.1±10.5 | 0.001 | −13.2±12.3 | 0.028 | −5.7±8.7 | 0.134 |
| Prothrombin time | 0.1 ±0.5 | 0.419 | 0.1±0.4 | 0.664 | −0.2±0.5 | 0.292 |
| I.N.R | 0.0±0.1 | 0.129 | 0.0±0.1 | 0.779 | 0.0±0.1 | 0.960 |
| aPTT | 2.1±4.5 | 0.032 | −0.3±4.7 | 0.864 | −0.9±4.1 | 0.598 |
| aPTTratio | 0.1±0.2 | 0.080 | 0.1±0.1 | 0.101 | 0.0±0.2 | 0.782 |
| Derived fibrinogen | 2.2±47.7 | 0.832 | −31±39.6 | 0.083 | −24=53.6 | 0.281 |
Data are expressed as mean ± SD